Zhonglin Hao is an Oncology physician affiliated with University of Kentucky. OpenAlex indexes 109 publications with 2,930 citations (h-index 25); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 Rose St
Lexington, KY 405360004
Telephone
859-257-1000Registry record last updated 6 Dec 2017.
Clinical trials
- ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
Sponsor: Zhonglin Hao
- Lung Cancer With Copanlisib and Durvalumab
Sponsor: Zhonglin Hao
- Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
Sponsor: Zhonglin Hao
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- Janssen Biotech, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20248 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
42.5%Opioid Agonist18.2%Oxycodone-Acetaminophen44%Oxycodone Hcl40%Morphine Sulfate Er16%Part D≥20 patientsPhenothiazine15.6%Prochlorperazine Maleate100%Part D≥61 patients+ 2 more classes in this area
Metabolism & gastrointestinal
25.9%Serotonin-3 Receptor Antagonist13.6%Ondansetron Hcl100%Part D≥29 patientsCorticosteroid12.3%Prednisone100%Part D≥24 patientsCancer & immunology
10.1%Kinase inhibitor5.8%Tagrisso69%Inlyta31%Part D<11 patientsCytochrome P450 17A1 Inhibitor2.5%Abiraterone Acetate100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety, tolerability, and preliminary efficacy results of a phase 1 study of LB2102, a dnTGFβRII armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC).
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
David Moliterno, MD
University of Kentucky
Robert Dipaola
University of Kentucky
Darwin Conwell, MD
University of Kentucky
Phillip Tibbs
University of Kentucky
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”